JAAD's 2024 impact factor is 11.8 with 38,702 citations.This places JAAD in the No. 1 position among 96 dermatology-related journals ranked by JCR in this period.JAADi reports an impressive debut ...

"We are excited that a journal as prestigious as JAAD has chosen to publish final data from our PSOARING 3 40-week extension efficacy and safety study of VTAMA® (tapinarof) Cream, 1% for adults ...

Dermavant Announces Publication of ADORING 1 & ADORING 2 Pivotal Phase 3 Trials of VTAMA® (tapinarof) cream, 1% for Adults and Children 2 Years of Age and Older with Atopic Dermatitis in JAAD ...